Syndax Pharmaceuticals announced that it has advanced into the Phase 1b portion of its Phase 1/2 proof-of-concept trial of revumenib, the company’s highly selective, oral menin inhibitor, as a monotherapy in patients with relapsed or refractory metastatic microsatellite stable colorectal cancer. The company’s decision was supported by the trial’s Independent Data Monitoring Committee following its recent pre-planned review of initial data from the Phase 1a portion of the trial.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNDX:
- Syndax added to Analyst Focus List at JPMorgan
- Syndax Pharmaceuticals Welcomes New Board Member, Passes Resolutions
- Syndax price target lowered to $30 from $32 at Citi
- Syndax reports Q1 EPS (85c), consensus (98c)
- Syndax Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Clinical and Business Update